Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | CES2 | O00748 | 1/20 | 0.47 |
| ▸ | CES1 | P23141 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | APAF1 | O14727 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | NOS2 | P35228 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8881340 | 0.83 | CES2 (0.50) | CES2CES1LMNAHIF1AKDM4E | |
| SCHEMBL28281150 | 0.80 | CES2 (0.47) | ALOX5CES2CES1LMNAHIF1A | |
| SCHEMBL28260719 | 0.79 | ALOX5 (0.55) | ALOX5EPHX1TRPM8LMNAADRA2A | |
| SCHEMBL341787 | 0.79 | ALOX5 (0.50) | ALOX5EPHX1TRPM8LMNAADRA2A | |
| SCHEMBL7475015 | 0.79 | ALOX5 (0.55) | ALOX5EPHX1TRPM8LMNAADRA2A | |
| SCHEMBL11566668 | 0.78 | TDP1 (0.53) | CES2CES1LMNAADRA2AHIF1A | |
| SCHEMBL5221261 | 0.78 | DPP4 (0.50) | ALOX5EPHX1TRPM8LMNAADRA2A | |
| SCHEMBL8376271 | 0.78 | CYP2D6 (0.52) | ALOX5EPHX1TRPM8LMNAADRA2A | |
| SCHEMBL8178447 | 0.78 | ALOX5 (0.48) | ALOX5EPHX1TRPM8LMNAADRA2A | |
| SCHEMBL13168073 | 0.77 | KMT2A (0.58) | CES2CES1LMNAAPAF1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120283236-A1 | Porphyrin Catalysts and Methods of Use Thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-11-08 | — | — | US | disclosed |
| US-8232267-B2 | Porphyrin catalysts and methods of use thereof | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2012-07-31 | — | — | US | disclosed |
| US-20100093688-A1 | Porphyrin catalysts and methods of use thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-04-15 | — | — | US | disclosed |
| WO-2008094222-A2 | PORPHYRIN CATALYSTS AND METHODS OF USE THEREOF | TRUSTEES OF PRINCETON (US) | 2008-08-07 | — | — | WO | disclosed |
| US-5968928-A | Excitatory amino acid antagonists: fused-azacyclic quinoxalinediones and immunoassays thereof | WARNER-LAMBERT COMPANY (US) | 1999-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283236-A1 | Porphyrin Catalysts and Methods of Use Thereof | PPOX, POR, MPO | ALOX5 1136/4885CES2 1196/4885CES1 1994/4885 |
| US-20100093688-A1 | Porphyrin catalysts and methods of use thereof | PPOX, POR, MPO | ALOX5 1136/4885CES2 1196/4885CES1 1994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.